PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib, rucaparib and niraparib have been approved for the treatment of ovarian cancer in the United States. Homologous recombination deficiency...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2019-04, Vol.23 (4), p.2303-2313
Main Authors: Jiang, Xuan, Li, Xiaoying, Li, Weihua, Bai, Huimin, Zhang, Zhenyu
Format: Article
Language:English
Subjects:
Anemia
Biomarkers
BRCA1/2
Breast cancer
Cancer therapies
Cell cycle
Chemotherapy
Clinical trials
Cold storage
Deoxyribonucleic acid
DNA
DNA damage
DNA repair
Drug Resistance, Neoplasm - genetics
FDA approval
Female
Genes
Genomic analysis
Genotype & phenotype
Homologous recombination
homologous recombination deficiency
Humans
Indazoles - adverse effects
Indazoles - therapeutic use
Indoles - adverse effects
Indoles - therapeutic use
Medical prognosis
Mutation
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
PARP inhibitor
Patients
Phthalazines - adverse effects
Phthalazines - therapeutic use
Piperazines - adverse effects
Piperazines - therapeutic use
Piperidines - adverse effects
Piperidines - therapeutic use
Platinum
Poly(ADP-ribose) polymerase
Poly(ADP-ribose) Polymerase Inhibitors - adverse effects
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Poly(ADP-ribose) Polymerases - genetics
resistance mechanism
Review
Reviews
Ribose
Targeted cancer therapy
Tumor cell lines
Tumors
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!